The effects of gender-affirming testosterone therapy in transgender men on the development of acne, acne severity and the relationship with clinical parameters: a three-year follow-up study

Rheumatoid Arthritis

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Ann Rheum Dis

Frazzei G, Landewé RBM, Wagenaar C, van de Stadt LA, van Schaardenburg D, Tas SW, van Vollenhoven RF

doi: 10.1016/j.ard.2025.01.042

Further Publications Rheumatology

One-year effectiveness of long-term exercise therapy in people with axial spondyloarthritis and severe functional limitations

Rheumatology (Oxford)

van Wissen MAT, van den Ende CHM, Gademan MGJ, Teuwen MMH, Peter WF, Mahler EAM, van Schaardenburg D, van Gaalen FA, Spoorenberg A, van den Hout WB, van Tubergen AM, Vliet Vlieland TPM, van Weely SFE

doi: 10.1093/rheumatology/keae323

Further Publications Immunology

Incidence of side effects associated with acetaminophen in people aged 65 years or more: a prospective cohort study using data from the Clinical Practice Research Datalink

Arthritis Care Res (Hoboken)

Kaur J, Nakafero G, Abhishek A, Mallen C, Doherty M, Zhang W

doi: 10.1002/acr.25471

Osteoarthritis

Do Existing MRI Definitions of Knee Osteoarthritis Identify Knees That Will Develop Clinically Significant Disease Over Up To 11 Years of Follow-Up?

Arthritis Rheumatol

Chang AH, Roemer FW, Guermazi A, Almagor O, Lee JJ, Chmiel JS, Muhammad LN, Song J, Sharma L

doi: 10.1002/art.42982

Further Publications Rheumatology

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Arthritis Res Ther

Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A

doi: 10.1186/s13075-024-03412-8

Osteoarthritis

Comparison of definitions of early knee osteoarthritis for likelihood of progression at 2-year and 5-year follow-up: the Multicenter Osteoarthritis Study

Ann Rheum Dis

Liew JW, Petrow E, Tilley S, LaValley MP, Roemer FW, Guermazi A, Lewis CE, Torner J, Nevitt MC, Lynch JA, Felson D

doi: 10.1136/ard-2024-226060

Further Publications Immunology

Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study

Pediatr Allergy Immunol

Agüera M, Soler-Garcia A, Alejandre C, Moussalam-Merino S, Sala-Castellví P, Pons G, Penela-Sánchez D, González-Grado C, Alsina-Rosell J, Climent C, Esteva C, Fortuny C, de-Sevilla MF, García-García JJ, Brotons P, Balaguer A, Estrada J, Jordan I, Muñoz-Almagro C, Launes C

doi: 10.1111/pai.14175

Atopic Dermatitis

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Acta Derm Venereol

Calabrese L, Cinotti E, D'Onghia M, Cartocci A, Rubegni P, Maccari F, Boulard C, Reguiai Z, Becherel PA, Jacobzone C, Begon E, Fite C, Walls B, Liegeon AL, Parier J, Chaby G, Perrot JL, Omcci Group

doi: 10.2340/actadv.v105.42275

Immune Response

Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial

Crit Care

Arns B, Kalil AC, Sorio GGL, Boschi E, Antonio ACP, Antonio JP, Birriel DC, Lanziotti DH, da Cunha Abbott F, Rocha GC, de Fátima Fernandes V, de Souza Dantas VC, da Silva Medeiros GF, de França Diniz Rocha V, Pereira FC, Gobatto ALN, Lima VP, Lacerda FH, de Maio Carrilho CMD, de Oliveira Cardozo KDN, Irineu VM, Kurtz P, Horvath JDC, Sesin GP, Agani CAJO, Dos Santos TM, Brochier LSB, da Rosa BS, Tomazini BM, Besen BAMP, Pereira AJ, Veiga VC, Nascimento GM, Zavascki AP, OPTIMISE Study Group

doi: 10.1186/s13054-024-05178-6

Related content